-
Mashup Score: 2
Key Points. We report a case of VITT following Ad26.COV2.S COVID-19 vaccination without radiographically demonstrable thrombosis at presentation.Early VITT reco
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Key Points. We report a case of VITT following Ad26.COV2.S COVID-19 vaccination without radiographically demonstrable thrombosis at presentation.Early VITT reco
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Anticoagulant therapy in patients with congenital FXI deficiency | Blood Advances | American Society of Hematology - 3 year(s) ago
Key Points. Bleeding risk of FXI deficiency on anticoagulation is unknown. We report 15 of 269 FXI-deficient subjects receiving VKA and/or DOACs. No major bleed
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4
Key Points. Fatal neurotoxicity developed 9 months after infusion of axi-cel in a patient treated for diffuse LBCL relapse after allogeneic hematopoietic cell t
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Key Points. Fatal neurotoxicity developed 9 months after infusion of axi-cel in a patient treated for diffuse LBCL relapse after allogeneic hematopoietic cell t
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Key Points. Fatal neurotoxicity developed 9 months after infusion of axi-cel in a patient treated for diffuse LBCL relapse after allogeneic hematopoietic cell t
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Key Points. Lymphoid blast transformation of an MPN with BCR-JAK2 was associated with detection of an IKZF1 deletion and upregulation of IL7R and CRLF2.Phenotyp
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations | Blood Advances | American Society of Hematology - 3 year(s) ago
Key Points. We describe the first cases of B-ALL in patients with RUNX1-FPD.We identify a novel germline RUNX1 mutation underlying RUNX1-FPD.
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Effective anti-BCMA retreatment in multiple myeloma | Blood Advances | American Society of Hematology - 3 year(s) ago
Key Points. We report clinical evidence of effectiveness using anti-BCMA therapies sequentially.Careful monitoring of the mechanism of relapse can help to guide
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Effective anti-BCMA retreatment in multiple myeloma | Blood Advances | American Society of Hematology - 3 year(s) ago
Key Points. We report clinical evidence of effectiveness using anti-BCMA therapies sequentially.Careful monitoring of the mechanism of relapse can help to guide
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Early VITT recognition and treatment with nonheparin anticoagulation can prevent severe thrombotic complications. https://t.co/64vCoMcg4u #exceptionalcasereport #clinicaltrialsandobservations #thrombosisandhemostasis https://t.co/Khl7F2EjzV